eDSP — NDA/BLA submission
H2 2026
Assuming positive study results, the company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.Source filing
QNCX biotech catalysts & pipeline
QUINCE THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
LAM-001 — Topline data
Q1 2027
Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027Source filing
LAM-001 — Topline data
Q1 2028
Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027Source filing
LAM-001 — Topline data
Q4 2028
The Phase 2 trial of LAM-001 in SAPH is anticipated to begin in late 2026, with data expected in the fourth quarter of 2028.Source filing